-57.7%
KORU vs GSK
+108.3%
-166.0%
-95.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.4% | +0.5% | -5.9% | -5.9% |
| 7D | +11.1% | +1.1% | +10.0% | +10.1% |
| 30D | -40.6% | +6.3% | -46.9% | -44.6% |
| 3M | -63.9% | +1.8% | -65.7% | -65.7% |
| 6M | -82.8% | +1.7% | -84.5% | -84.6% |
| YTD | -15.4% | +6.5% | -21.9% | -28.0% |
| 1Y | -3.3% | +9.5% | -12.7% | -19.8% |
| 3Y | +136.2% | +65.3% | +70.9% | +15.0% |
| 5Y | -36.7% | +43.7% | -80.4% | -65.2% |
| 10Y | -22.9% | +104.1% | -127.0% | -69.4% |
| All | -57.7% | +108.3% | -166.0% | -79.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling